13F Holdings
中文EN

AYTU AYTU BIOPHARMA, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1385818 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.1%
TTM net income YoY-53.8%
TTM EPS YoY-55.0%
Revenue 3-yr CAGR-15.7%
Net income 3-yr CAGR—

Margins

Gross margin63.3%
Operating margin-18.4%
Net margin-34.3%
FCF margin—
EBITDA margin-14.2%

Returns

ROE-73.4%
ROA-17.9%
ROIC (approx.)-87.4%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets68.2%
Debt / equity0.33x
Current ratio1.07x
Interest coverage-6.01x

Cash quality & payout

Operating cash flow / net income-0.18x
Accruals ratio-21.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$57.57M$66.38M$65.18M$107.40M$96.67M
Cost of revenue$20.75M$20.55M$16.13M$40.77M$44.39M
Gross profit$36.82M$45.83M$49.05M$66.63M$52.28M
R&D expense$0$1.33M$2.77M$4.09M$12.66M
SG&A expense$19.27M$17.38M$19.95M$28.63M$31.17M
Operating income-$8.31M-$7.83M-$1.59M-$17.07M-$109.91M
Interest expense$1.90M$3.70M$5.06M$4.96M$900,000
Pretax income-$14.23M-$13.74M-$10.38M-$17.05M-$108.89M
Income tax$21,000$437,000$2.14M$0-$110,000
Net income-$14.25M-$13.56M-$15.84M-$17.05M-$108.78M
EBITDA-$4.38M-$2.45M$5.13M-$8.25M-$99.76M
EPS (basic)-1.16-2.16-2.86-5.11-74.01
EPS (diluted)———-5.11-74.01
Weighted avg. shares (diluted)———3.34M1.47M
Balance sheet
Cash & equivalents$26.31M$30.95M$20.01M$22.98M$19.36M
Receivables$22.78M$31.16M$23.53M$28.94M$21.71M
Inventory$6.86M$11.43M$12.14M$11.99M$10.85M
Current assets$61.76M$79.18M$61.89M$72.83M$59.93M
PP&E, net$385,000$532,000$693,000$1.81M$3.02M
Goodwill———$0$0
Intangibles$41.40M$42.20M$52.45M$58.97M$70.63M
Total assets$105.01M$124.18M$118.09M$136.46M$137.62M
Current liabilities$54.66M$63.06M$62.23M$69.02M$64.44M
Short-term debt$1.86M$1.86M$1.86M$85,000$3.81M
Long-term debt$9.10M$10.89M$10.88M$14.71M$14.28M
Total debt$10.96M$12.75M$12.73M$14.80M$18.09M
Total liabilities$69.73M$105.21M$90.38M$97.11M$93.31M
Shareholders' equity$35.27M$18.97M$27.72M$39.36M$44.31M
Net debt-$15.35M-$18.20M-$7.27M-$8.19M-$1.27M
Shares outstanding10.73M8.98M5.97M5.52M1.93M
Cash flow statement
Operating cash flow$3.28M-$1.94M-$1.39M-$5.13M-$28.82M
Capital expenditure$29,000$228,000$329,000—$0
Free cash flow$3.25M-$2.17M-$1.72M—-$28.82M
Investing cash flow-$29,000-$2.56M-$329,000-$117,000-$3.25M
Financing cash flow-$7.90M$15.44M-$1.26M$8.87M$1.53M
Depreciation & amortization$3.93M$5.38M$6.72M$8.81M$10.15M
Stock-based compensation$691,000$576,000$2.37M$6.05M$5.25M

Free plan shows the latest 5 periods; Pro shows all 21 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.